Primary and secondary prevention of stroke by antihypertensive treatment in clinical trials

Current Hypertension Reports

Volumn 9, Issue 4, 2007, Pages 299-304

  Grassi, Guido ^a   Arenare, Francesca ^b   Trevano, Fosca Quarti ^b   Dell'Oro, Raffaella ^b   Mancia, Giuseppe ^b  

^a SAN GERARDO HOSPITAL   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ANGIOTENSIN; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EPROSARTAN; HYDROCHLOROTHIAZIDE; LOSARTAN; NITRENDIPINE; PERINDOPRIL; PLACEBO; RENIN;

AGE; BLOOD PRESSURE REGULATION; CEREBROVASCULAR DISEASE; CIGARETTE SMOKING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; HUMAN; HYPERTENSION; HYPOTENSION; INCOME; MORTALITY; NEUROPROTECTION; PRIMARY PREVENTION; RACE DIFFERENCE; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SECONDARY PREVENTION; STROKE; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CLINICAL TRIALS AS TOPIC; HUMANS; HYPERTENSION; PRIMARY PREVENTION; RISK FACTORS; STROKE;

EID: 34548499309     PISSN: 15226417     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11906-007-0055-x     Document Type: Review

References (39)

1. Kearney PM, Whelton M, Reynolds K, et al.: Global burden of hypertension: analysis of worldwide data. Lancet 2005, 365:217-223.
2. Kjeldsen SE, Julius S, Hedner T, Hansson L: Stroke is more common than myocardial infarction in hypertension: analysis based on 11 major randomized intervention trials. Blood Press 2001, 10:190-192.
3. Lewington S, Clarke R, Qizilbash N, et al.: Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002, 360:1903-1913.
4. Lawes CM, Bennett DA, Feigin VL, Rodgers A: Blood pressure and stroke: an overview of published reviews. Stroke 2004, 35:776-785.
5. Kannel WB, Wolf PA, Verter J, McNamara PM: Epidemiologic assessment of the role of blood pressure in stroke. The Framingham study. JAMA 1970, 214:301-310.
6. MacMahon S, Peto R, Cutler J, et al.: Blood pressure, stroke, and coronary heart disease. Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990, 335:765-774.
7. Kannel WB, Wolf PA, McGee DL, et al.: Systolic blood pressure, arterial rigidity, and risk of stroke. The Framingham study. JAMA 1981, 245:1225-1229.
8. Domanski MJ, Davis BR, Pfeffer MA, et al.: Isolated systolic hypertension: prognostic information provided by pulse pressure. Hypertension 1999, 34:375-380.
9. Truelsen T, Prescott E, Gronbaek M, et al.: Trends in stroke incidence. The Copenhagen city heart study. Stroke 1997, 28:1903-1907.
10. Madhavan S, Ooi WL, Cohen H, Alderman MH: Relation of pulse pressure and blood pressure reduction to the incidence of myocardial infarction. Hypertension 1994, 23:395-401.
11. Benetos A, Rudnichi A, Safar M, Guize L: Pulse pressure and cardiovascular mortality in normotensive and hypertensive subjects. Hypertension 1998, 32:560-564.
12. Nielsen WB, Lindenstrom E, Vestbo J, Jensen GB: Is diastolic hypertension an independent risk factor for stroke in the presence of normal systolic blood pressure in the middle-aged and elderly? Am J Hypertens 1997, 10:634-639.
13. Williams B, Lacy PS, Thom SM, et al.: Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006, 113:1213-1225.
14. Straus SE, Majumdar SR, McAlister FA: New evidence for stroke prevention: scientific review. JAMA 2002, 288:1388-1395.
15. Chalmers J, Todd A, Chapman N, et al.: International Society of Hypertension (ISH): statement on blood pressure lowering and stroke prevention. J Hypertens 2003, 21:651-663.
16. Staessen JA, Wang JG, Thijs L: Cardiovascular protection and blood pressure reduction: a meta-analysis. Lancet 2001, 358:1305-1315.
17. Gueyffier F, Boissel JP, Boutitie F, et al.: Effect of antihypertensive treatment in patients having already suffered from stroke. Gathering the evidence. The INDANA (Individual Data Analysis of Antihypertensive Intervention Trials) project collaborators. Stroke 1997, 28:2557-2562.
18. Hansson L, Zanchetti A, Carruthers SG, et al.: Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT study group. Lancet 1998, 351:1755-1762.
19. Bilous R: Blood pressure control in type 2 diabetes: what does the United Kingdom prospective diabetes study (UKPDS) tell us? Nephrol Dial Transplant 1999, 14:2562-2564.
20. Hebert PR, Moser M, Mayer J, et al.: Recent evidence on drug therapy of mild to moderate hypertension and decreased risk of coronary heart disease. Arch Intern Med 1993, 153:578-581.
21. Gueyffier F, Bulpitt C, Boissel JP, et al.: Antihypertensive drugs in very old people: a subgroup meta-analysis of randomised controlled trials. INDANA group. Lancet 1999, 353:793-796.
22. Wright JM, Lee CH, Chambers GK: Systematic review of antihypertensive therapies: does the evidence assist in choosing a first-line drug? CMAJ 1999, 161:25-32.
23. Psaty BM, Smith NL, Siscovick DS, et al.: Health outcomes associated with antihypertensive therapies used as first-line agents. A systematic review and meta-analysis. JAMA 1997, 277:739-745.
24. Neal B, MacMahon S, Chapman N: Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Lancet 2000, 356:1955-1964.
25. McAlister FA, Sackett DL: Active-control equivalence trials and antihypertensive agents. Am J Med 2001, 111:553-558.
26. Mancia G, Grassi G: Systolic and diastolic blood pressure control in antihypertensive drug trials. J Hypertens 2002, 20:1461-1464.
27. Klungel OH, Stricker BH, Paes AH, et al.: Excess stroke among hypertensive men and women attributable to under-treatment of hypertension. Stroke 1999, 30:1312-1318.
28. Andersson OK, Almgren T, Persson B, et al.: Survival in treated hypertension: follow up study after two decades. BMJ 1998, 317:167-171.
29. Benetos A, Thomas F, Bean KE, Guize L: Why cardiovascular mortality is higher in treated hypertensives versus subjects of the same age, in the general population. J Hypertens 2003, 21:1635-1640.
30. Hansson L, Lindholm LH, Niskanen L, et al.: Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999, 353:611-616.
31. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group: The antihypertensive and lipid-lowering treatment to prevent heart attack trial: major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002, 288:2981-2997.
32. Lithell H, Hansson L, Skoog I, et al.: The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003, 21:875-886.
33. Dahlof B, Devereux RB, Kjeldsen SE, et al.: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002, 359:995-1003.
34. Mancia G, Grassi G: Secondary prevention of stroke: old and new evidence. Aging Clin Exp Res 2002, 14:216-220.
35. Adams HP Jr: Stroke: a vascular pathology with inadequate management. J Hypertens 2003, 21(Suppl 5):S3-S7.
36. MacMahon S: Blood pressure and the prevention of stroke. J Hypertens 1996, 14(Suppl 6):S39-S46.
37. PATS Collaborating Group: Post-stroke antihypertensive treatment study. A preliminary result. Chin Med J 1995, 108:710-717.
38. PROGRESS Collaborative Group: Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 2001, 358:1033-1041.
39. Schrader J, Luders S, Kulschewski A, et al.: Morbidity and mortality after stroke, eprosartan compared with nitrendipine for secondary prevention: principal results of a prospective randomized controlled study (MOSES). Stroke 2005, 36:1218-1226.